BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla (BCAB), a clinical-stage biotech company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, has announced an upcoming poster presentation at the 2025 ASCO Annual Meeting. The event will be held both online and at Chicago's McCormick Place Convention Center from May 30–June 3, 2025.
The presentation will feature Phase 2 trial results of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in treating patients with heavily pretreated squamous cell carcinoma of the head and neck. The poster presentation (Abstract #6048, Poster #456) is scheduled for Monday, June 2, 2025, from 9:00 AM to 12:00 PM CDT during the Head and Neck Cancer session.
BioAtla (BCAB), un'azienda biotecnologica in fase clinica specializzata in anticorpi terapeutici Conditionally Active Biologic (CAB) per tumori solidi, ha annunciato una prossima presentazione poster al 2025 ASCO Annual Meeting. L'evento si terrà sia online che al McCormick Place Convention Center di Chicago dal 30 maggio al 3 giugno 2025.
La presentazione mostrerà i risultati dello studio di Fase 2 di ozuriftamab vedotin (BA3021), un ROR2-ADC a legame condizionale, nel trattamento di pazienti con carcinoma squamoso della testa e del collo fortemente pretrattati. Il poster (Abstract #6048, Poster #456) è previsto per lunedì 2 giugno 2025, dalle 9:00 alle 12:00 CDT durante la sessione sul cancro della testa e del collo.
BioAtla (BCAB), una empresa biotecnológica en etapa clínica especializada en terapias con anticuerpos Conditionally Active Biologic (CAB) para tumores sólidos, ha anunciado una próxima presentación en formato póster en la Reunión Anual ASCO 2025. El evento se realizará tanto en línea como en el Centro de Convenciones McCormick Place de Chicago, del 30 de mayo al 3 de junio de 2025.
La presentación incluirá resultados del ensayo de Fase 2 de ozuriftamab vedotin (BA3021), un ROR2-ADC de unión condicional, para el tratamiento de pacientes con carcinoma de células escamosas de cabeza y cuello con múltiples tratamientos previos. La presentación en póster (Resumen #6048, Póster #456) está programada para el lunes 2 de junio de 2025, de 9:00 a 12:00 CDT, durante la sesión de cáncer de cabeza y cuello.
BioAtla (BCAB)는 고형암을 위한 조건부 활성 생물학적(CAB) 항체 치료제에 특화된 임상 단계의 바이오테크 기업으로, 2025 ASCO 연례회의에서 포스터 발표를 할 예정임을 발표했습니다. 이번 행사는 2025년 5월 30일부터 6월 3일까지 시카고 맥코믹 플레이스 컨벤션 센터와 온라인에서 동시에 개최됩니다.
발표에서는 다중 치료를 받은 두경부 편평세포암 환자 치료를 위한 조건부 결합 ROR2-ADC인 ozuriftamab vedotin (BA3021)의 2상 임상 결과가 소개됩니다. 포스터 발표(초록 #6048, 포스터 #456)는 2025년 6월 2일 월요일 오전 9시부터 정오까지 CDT 시간대에 두경부암 세션에서 진행됩니다.
BioAtla (BCAB), une société biotechnologique en phase clinique spécialisée dans les anticorps thérapeutiques Conditionally Active Biologic (CAB) pour les tumeurs solides, a annoncé une prochaine présentation sous forme de poster lors du Congrès annuel ASCO 2025. L'événement se tiendra à la fois en ligne et au McCormick Place Convention Center de Chicago, du 30 mai au 3 juin 2025.
La présentation portera sur les résultats de l’essai de phase 2 de ozuriftamab vedotin (BA3021), un ROR2-ADC à liaison conditionnelle, dans le traitement de patients atteints d’un carcinome épidermoïde de la tête et du cou, fortement prétraités. Le poster (Résumé #6048, Poster #456) est prévu pour le lundi 2 juin 2025, de 9h00 à 12h00 CDT, lors de la session sur le cancer de la tête et du cou.
BioAtla (BCAB), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Conditionally Active Biologic (CAB) Antikörpertherapeutika für solide Tumoren spezialisiert hat, hat eine bevorstehende Posterpräsentation auf dem 2025 ASCO Annual Meeting angekündigt. Die Veranstaltung findet vom 30. Mai bis 3. Juni 2025 sowohl online als auch im McCormick Place Convention Center in Chicago statt.
Die Präsentation wird Ergebnisse der Phase-2-Studie von ozuriftamab vedotin (BA3021), einem bedingt bindenden ROR2-ADC, bei der Behandlung von Patienten mit stark vorbehandeltem Plattenepithelkarzinom des Kopf- und Halsbereichs vorstellen. Die Posterpräsentation (Abstract #6048, Poster #456) ist für Montag, den 2. Juni 2025, von 9:00 bis 12:00 Uhr CDT während der Sitzung zu Kopf- und Halskrebs geplant.
- None.
- None.
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held online and at the McCormick Place Convention Center in Chicago, Illinois from May 30–June 3, 2025.
| Presentation Details: | |
| Title: | Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck |
| Abstract Number: | 6048 |
| Session Type: | Poster #456 |
| Session Title: | Head and Neck Cancer |
| Session Date and Time: | Monday, June 2, 2025; 9:00 AM – 12:00 PM CDT |
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
What will BioAtla (BCAB) present at ASCO 2025?
When is BioAtla's (BCAB) presentation scheduled at ASCO 2025?
What type of cancer treatment is BioAtla (BCAB) developing with ozuriftamab vedotin?
Where can investors find BioAtla's (BCAB) ASCO 2025 presentation materials?
